Cargando…
Empagliflozin in Patients with Chronic Kidney Disease
BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligib...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614055/ https://www.ncbi.nlm.nih.gov/pubmed/36331190 http://dx.doi.org/10.1056/NEJMoa2204233 |
_version_ | 1783605559178559488 |
---|---|
author | Herrington, William G. Staplin, Natalie Wanner, Christoph Green, Jennifer B. Hauske, Sibylle J. Emberson, Jonathan R. Preiss, David Judge, Parminder Mayne, Kaitlin J. Ng, Sarah Y.A. Sammons, Emily Zhu, Doreen Hill, Michael Stevens, Will Wallendszus, Karl Brenner, Susanne Cheung, Alfred K. Liu, Zhi-Hong Li, Jing Hooi, Lai Seong Liu, Wen Kadowaki, Takashi Nangaku, Masaomi Levin, Adeera Cherney, David Maggioni, Aldo P. Pontremoli, Roberto Deo, Rajat Goto, Shinya Rossello, Xavier Tuttle, Katherine R. Steubl, Dominik Petrini, Michaela Massey, Dan Eilbracht, Jens Brueckmann, Martina Landray, Martin J. Baigent, Colin Haynes, Richard |
author_facet | Herrington, William G. Staplin, Natalie Wanner, Christoph Green, Jennifer B. Hauske, Sibylle J. Emberson, Jonathan R. Preiss, David Judge, Parminder Mayne, Kaitlin J. Ng, Sarah Y.A. Sammons, Emily Zhu, Doreen Hill, Michael Stevens, Will Wallendszus, Karl Brenner, Susanne Cheung, Alfred K. Liu, Zhi-Hong Li, Jing Hooi, Lai Seong Liu, Wen Kadowaki, Takashi Nangaku, Masaomi Levin, Adeera Cherney, David Maggioni, Aldo P. Pontremoli, Roberto Deo, Rajat Goto, Shinya Rossello, Xavier Tuttle, Katherine R. Steubl, Dominik Petrini, Michaela Massey, Dan Eilbracht, Jens Brueckmann, Martina Landray, Martin J. Baigent, Colin Haynes, Richard |
collection | PubMed |
description | BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligibility required an estimated glomerular filtration rate (eGFR) of ≥20 to <45 ml/minute/1.73m(2); or ≥45 to <90 ml/minute/1.73m(2) with a urinary albumin-to-creatinine ratio (ACR) of ≥200 mg/g. The primary outcome was a composite of kidney disease progression (end-stage kidney disease, a sustained eGFR <10 ml/minute/1.73m(2), a sustained decline in eGFR of ≥40%, or a renal death) or death from cardiovascular causes. RESULTS: During a median of 2.0 years follow-up, a primary outcome event occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% CI 0.64 to 0.82; P<0.001), with consistent results in those with or without diabetes and across the range of eGFR studied. There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003), but no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%), or death from any cause (4.5% vs 5.1%). The rates of serious adverse events were broadly similar in the two groups. CONCLUSIONS: Empagliflozin reduced the risk of the composite outcome of kidney disease progression or cardiovascular death in a wide range of patients at risk of CKD progression. (Funding:Boehringer Ingelheim, Eli Lilly and others; Clinicaltrials.gov:NCT03594110, EuDRACT: 2017-002971-24). |
format | Online Article Text |
id | pubmed-7614055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-76140552023-01-12 Empagliflozin in Patients with Chronic Kidney Disease Herrington, William G. Staplin, Natalie Wanner, Christoph Green, Jennifer B. Hauske, Sibylle J. Emberson, Jonathan R. Preiss, David Judge, Parminder Mayne, Kaitlin J. Ng, Sarah Y.A. Sammons, Emily Zhu, Doreen Hill, Michael Stevens, Will Wallendszus, Karl Brenner, Susanne Cheung, Alfred K. Liu, Zhi-Hong Li, Jing Hooi, Lai Seong Liu, Wen Kadowaki, Takashi Nangaku, Masaomi Levin, Adeera Cherney, David Maggioni, Aldo P. Pontremoli, Roberto Deo, Rajat Goto, Shinya Rossello, Xavier Tuttle, Katherine R. Steubl, Dominik Petrini, Michaela Massey, Dan Eilbracht, Jens Brueckmann, Martina Landray, Martin J. Baigent, Colin Haynes, Richard N Engl J Med Article BACKGROUND: This study, the EMPA-KIDNEY trial, was designed to assess the effects of empagliflozin in a broad range of patients with chronic kidney disease (CKD) at risk of progression. METHODS: We randomly assigned 6609 participants to empagliflozin (10mg once daily) versus matching placebo. Eligibility required an estimated glomerular filtration rate (eGFR) of ≥20 to <45 ml/minute/1.73m(2); or ≥45 to <90 ml/minute/1.73m(2) with a urinary albumin-to-creatinine ratio (ACR) of ≥200 mg/g. The primary outcome was a composite of kidney disease progression (end-stage kidney disease, a sustained eGFR <10 ml/minute/1.73m(2), a sustained decline in eGFR of ≥40%, or a renal death) or death from cardiovascular causes. RESULTS: During a median of 2.0 years follow-up, a primary outcome event occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% CI 0.64 to 0.82; P<0.001), with consistent results in those with or without diabetes and across the range of eGFR studied. There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003), but no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%), or death from any cause (4.5% vs 5.1%). The rates of serious adverse events were broadly similar in the two groups. CONCLUSIONS: Empagliflozin reduced the risk of the composite outcome of kidney disease progression or cardiovascular death in a wide range of patients at risk of CKD progression. (Funding:Boehringer Ingelheim, Eli Lilly and others; Clinicaltrials.gov:NCT03594110, EuDRACT: 2017-002971-24). 2023-01-12 2022-11-04 /pmc/articles/PMC7614055/ /pubmed/36331190 http://dx.doi.org/10.1056/NEJMoa2204233 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a CC BY-ND 4.0 (https://creativecommons.org/licenses/by-nd/4.0/) International license. |
spellingShingle | Article Herrington, William G. Staplin, Natalie Wanner, Christoph Green, Jennifer B. Hauske, Sibylle J. Emberson, Jonathan R. Preiss, David Judge, Parminder Mayne, Kaitlin J. Ng, Sarah Y.A. Sammons, Emily Zhu, Doreen Hill, Michael Stevens, Will Wallendszus, Karl Brenner, Susanne Cheung, Alfred K. Liu, Zhi-Hong Li, Jing Hooi, Lai Seong Liu, Wen Kadowaki, Takashi Nangaku, Masaomi Levin, Adeera Cherney, David Maggioni, Aldo P. Pontremoli, Roberto Deo, Rajat Goto, Shinya Rossello, Xavier Tuttle, Katherine R. Steubl, Dominik Petrini, Michaela Massey, Dan Eilbracht, Jens Brueckmann, Martina Landray, Martin J. Baigent, Colin Haynes, Richard Empagliflozin in Patients with Chronic Kidney Disease |
title | Empagliflozin in Patients with Chronic Kidney Disease |
title_full | Empagliflozin in Patients with Chronic Kidney Disease |
title_fullStr | Empagliflozin in Patients with Chronic Kidney Disease |
title_full_unstemmed | Empagliflozin in Patients with Chronic Kidney Disease |
title_short | Empagliflozin in Patients with Chronic Kidney Disease |
title_sort | empagliflozin in patients with chronic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614055/ https://www.ncbi.nlm.nih.gov/pubmed/36331190 http://dx.doi.org/10.1056/NEJMoa2204233 |
work_keys_str_mv | AT empagliflozininpatientswithchronickidneydisease AT herringtonwilliamg empagliflozininpatientswithchronickidneydisease AT staplinnatalie empagliflozininpatientswithchronickidneydisease AT wannerchristoph empagliflozininpatientswithchronickidneydisease AT greenjenniferb empagliflozininpatientswithchronickidneydisease AT hauskesibyllej empagliflozininpatientswithchronickidneydisease AT embersonjonathanr empagliflozininpatientswithchronickidneydisease AT preissdavid empagliflozininpatientswithchronickidneydisease AT judgeparminder empagliflozininpatientswithchronickidneydisease AT maynekaitlinj empagliflozininpatientswithchronickidneydisease AT ngsarahya empagliflozininpatientswithchronickidneydisease AT sammonsemily empagliflozininpatientswithchronickidneydisease AT zhudoreen empagliflozininpatientswithchronickidneydisease AT hillmichael empagliflozininpatientswithchronickidneydisease AT stevenswill empagliflozininpatientswithchronickidneydisease AT wallendszuskarl empagliflozininpatientswithchronickidneydisease AT brennersusanne empagliflozininpatientswithchronickidneydisease AT cheungalfredk empagliflozininpatientswithchronickidneydisease AT liuzhihong empagliflozininpatientswithchronickidneydisease AT lijing empagliflozininpatientswithchronickidneydisease AT hooilaiseong empagliflozininpatientswithchronickidneydisease AT liuwen empagliflozininpatientswithchronickidneydisease AT kadowakitakashi empagliflozininpatientswithchronickidneydisease AT nangakumasaomi empagliflozininpatientswithchronickidneydisease AT levinadeera empagliflozininpatientswithchronickidneydisease AT cherneydavid empagliflozininpatientswithchronickidneydisease AT maggionialdop empagliflozininpatientswithchronickidneydisease AT pontremoliroberto empagliflozininpatientswithchronickidneydisease AT deorajat empagliflozininpatientswithchronickidneydisease AT gotoshinya empagliflozininpatientswithchronickidneydisease AT rosselloxavier empagliflozininpatientswithchronickidneydisease AT tuttlekatheriner empagliflozininpatientswithchronickidneydisease AT steubldominik empagliflozininpatientswithchronickidneydisease AT petrinimichaela empagliflozininpatientswithchronickidneydisease AT masseydan empagliflozininpatientswithchronickidneydisease AT eilbrachtjens empagliflozininpatientswithchronickidneydisease AT brueckmannmartina empagliflozininpatientswithchronickidneydisease AT landraymartinj empagliflozininpatientswithchronickidneydisease AT baigentcolin empagliflozininpatientswithchronickidneydisease AT haynesrichard empagliflozininpatientswithchronickidneydisease |